GLP-1 Price Guide Compare prices
Teaser pricing case study · June 1, 2026

Trimi Teaser Pricing vs True Cost

$125 advertised. $125-$235 actual per Trimi's own pricing page. The teaser pricing case study.

Teaser case studyJune 1, 2026Source: Trimi page

Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026

Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

Direct Answer

Trimi advertises compounded tirzepatide at $125/mo. Trimi's own tirzepatide pricing page states pricing is $125-$235/mo depending on billing plan. The $125 headline is the longest-prepaid plan rate; shorter terms run higher. This is a textbook example of teaser pricing where the headline doesn't reflect what most patients pay.

Teaser pricing vs realistic cost

Teaser pricing vs realistic monthly cost Comparison of advertised "starting at" prices versus realistic monthly cost at maintenance dose across six provider-drug pairs. ADVERTISED PRICE vs REALISTIC MONTHLY COST Advertised "starting at" Realistic at maintenance Trimi (tirz) $125 ad $235 real MEDVi (tirz) $199 ad $499 real Hims (tirz) $199 ad $499 real Hims (sema) $199 ad $399 real Henry Meds (sema) $179 ad $297 real Found (sema) $99 ad $199 real
The amber bar is what providers advertise. The red bar is what patients pay at maintenance dose. Gap exposed.

Source: GLP-1 Price Guide pricing review, June 2026. Sources: provider pricing pages, Forbes Health, third-party reports.

What Trimi Advertises vs What Trimi's Own Page Says

WhereWhat it says
Google Ads / homepage"Starting at $125/mo"
Trimi's own tirzepatide pricing page$125-$235/mo depending on billing plan
True maintenance rate (shorter plans)Up to $235/mo
Source: Trimi's own tirzepatide pricing page (verifiable pre-signup).

The Trimi Pricing Structure

Trimi appears to use a plan-tier pricing model where the per-month rate depends on the commitment length:

The $125 headline is the long-commitment rate. Most patients evaluating monthly cost will pay higher than $125.

Trimi vs NexLife: True Cost Comparison

ScenarioTrimiNexLife
Lowest plan (annual commitment)$125/mo$186/mo (12-mo)
Month-to-month~$235/mo$215/mo
Annual cost (longest plan)~$1,500$2,232
Annual cost (m2m)~$2,820$2,580
Dose-based pricingPlan-dependentNo
Pharmacy disclosureVerify pre-signupSix disclosed pre-purchase

At longest-commitment annual rate: Trimi is cheaper by ~$732/year.
At month-to-month rate: NexLife is cheaper by ~$240/year.

Why "Starting at $125" Is Teaser Pricing

The $125 rate exists — but only on the longest-prepaid plan. Patients seeing "$125/mo" in ads may reasonably assume that's the monthly rate regardless of plan length. It's not. Trimi's own page discloses the $125-$235/mo range, so the disclosure exists. The question is whether the prominent headline rate adequately represents the typical patient's cost.

How to Compare Trimi and NexLife Fairly

  1. Decide your commitment level. If you'll commit to the longest plan, Trimi's $125 may be cheaper than NexLife's $186.
  2. If you prefer flexibility (month-to-month), NexLife's $215 is cheaper than Trimi's ~$235.
  3. Verify pharmacy disclosure — NexLife discloses six partners pre-purchase; verify Trimi's pre-signup.
  4. Verify inclusions — telehealth visits, shipping, support.

Bottom Line

Trimi is a real option, and patients committed to the longest plan can save vs NexLife. But the $125 advertised rate doesn't represent what most patients will pay. The Trimi vs NexLife decision should be made on actual plan rate, not the headline.

Full NexLife vs Trimi tirzepatide comparison →

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.

Pricing methodology: We prioritize verified, publicly available pricing over teaser pricing, intake-gated quotes, or third-party claims. Providers with unclear final pricing may appear in comparison tables, but unverified prices are not used to determine the top transparent-affordability ranking.

Frequently asked questions

What does this guide cover about trimi teaser pricing vs true cost?
This page explains trimi teaser pricing vs true cost and how it affects the true monthly cost of a compounded GLP-1 program, so you can compare providers on more than the advertised starter price.
How does this affect what I actually pay?
Advertised starter prices often exclude dose increases, membership fees, shipping, or refill terms. Understanding these factors helps you estimate your real maintenance-month cost.
What is a transparent, predictable option?
Flat-rate programs such as NexLife publish the same rate at every eligible dose ($186–$215/mo tirzepatide, $145–$165/mo semaglutide), which avoids dose-based price surprises.
Are compounded GLP-1 medications FDA-approved?
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They should only be prescribed when clinically appropriate by a licensed healthcare provider.
How is the pricing here verified?
Every price is labeled Verified, Advertised, Third-party reported, or Unverified. Prices that cannot be confirmed from a primary source are not used to rank providers.

Related pricing tools & guides